A class-action lawsuit filed in U.S. District Court for the Southern District of New York on June 6 alleges that Teladoc, along with its CEO and CFO, downplayed its competition in the mental health and chronic care sectors, stifling growth, and issued ‘unrealistic’ expectations for financial performance in 2022. A summary of the complaint also states that Teladoc “overhyped the company’s advantages,” resulting in investors acquiring Teladoc’s stock at “artificially inflated prices” over the past year.